Logo image of VAPO

VAPOTHERM INC (VAPO) Stock Fundamental Analysis

NYSE:VAPO - New York Stock Exchange, Inc. - US9221073052 - Common Stock - Currency: USD

1.27  +0.08 (+6.72%)

Fundamental Rating

2

Taking everything into account, VAPO scores 2 out of 10 in our fundamental rating. VAPO was compared to 189 industry peers in the Health Care Equipment & Supplies industry. VAPO has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, VAPO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year VAPO has reported negative net income.
In the past year VAPO has reported a negative cash flow from operations.
VAPO had negative earnings in each of the past 5 years.
VAPO had a negative operating cash flow in each of the past 5 years.
VAPO Yearly Net Income VS EBIT VS OCF VS FCFVAPO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -86.17%, VAPO is doing worse than 79.70% of the companies in the same industry.
Industry RankSector Rank
ROA -86.17%
ROE N/A
ROIC N/A
ROA(3y)-59.67%
ROA(5y)-53.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VAPO Yearly ROA, ROE, ROICVAPO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400

1.3 Margins

Looking at the Gross Margin, with a value of 36.12%, VAPO is doing worse than 66.83% of the companies in the same industry.
In the last couple of years the Gross Margin of VAPO has declined.
VAPO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 36.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.95%
GM growth 5Y-5.98%
VAPO Yearly Profit, Operating, Gross MarginsVAPO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100 -150

2

2. Health

2.1 Basic Checks

VAPO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VAPO has more shares outstanding
The debt/assets ratio for VAPO is higher compared to a year ago.
VAPO Yearly Shares OutstandingVAPO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M
VAPO Yearly Total Debt VS Total AssetsVAPO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -9.96, we must say that VAPO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VAPO (-9.96) is worse than 76.73% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.96
ROIC/WACCN/A
WACC10.3%
VAPO Yearly LT Debt VS Equity VS FCFVAPO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

VAPO has a Current Ratio of 3.04. This indicates that VAPO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of VAPO (3.04) is comparable to the rest of the industry.
A Quick Ratio of 1.61 indicates that VAPO should not have too much problems paying its short term obligations.
VAPO has a worse Quick ratio (1.61) than 66.83% of its industry peers.
Industry RankSector Rank
Current Ratio 3.04
Quick Ratio 1.61
VAPO Yearly Current Assets VS Current LiabilitesVAPO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

5

3. Growth

3.1 Past

VAPO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.56%, which is quite impressive.
The Revenue has decreased by -3.95% in the past year.
VAPO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.41% yearly.
EPS 1Y (TTM)34.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.64%
Revenue 1Y (TTM)-3.95%
Revenue growth 3Y11.57%
Revenue growth 5Y13.41%
Sales Q2Q%11.96%

3.2 Future

The Earnings Per Share is expected to grow by 18.76% on average over the next years. This is quite good.
VAPO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.62% yearly.
EPS Next Y81.61%
EPS Next 2Y35.65%
EPS Next 3Y23.77%
EPS Next 5Y18.76%
Revenue Next Year5.53%
Revenue Next 2Y10.65%
Revenue Next 3Y11.78%
Revenue Next 5Y18.62%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VAPO Yearly Revenue VS EstimatesVAPO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
VAPO Yearly EPS VS EstimatesVAPO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -10 -20 -30

1

4. Valuation

4.1 Price/Earnings Ratio

VAPO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VAPO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VAPO Price Earnings VS Forward Price EarningsVAPO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VAPO Per share dataVAPO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as VAPO's earnings are expected to grow with 23.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.65%
EPS Next 3Y23.77%

0

5. Dividend

5.1 Amount

No dividends for VAPO!.
Industry RankSector Rank
Dividend Yield N/A

VAPOTHERM INC

NYSE:VAPO (12/14/2023, 8:19:45 PM)

1.27

+0.08 (+6.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-08 2023-11-08/amc
Earnings (Next)02-21 2024-02-21/amc
Inst Owners0.01%
Inst Owner Change-99.24%
Ins Owners75.19%
Ins Owner Change0%
Market Cap7.80M
Analysts45
Price Target1.02 (-19.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.52%
Min EPS beat(2)-12.72%
Max EPS beat(2)15.76%
EPS beat(4)2
Avg EPS beat(4)0.97%
Min EPS beat(4)-12.72%
Max EPS beat(4)15.76%
EPS beat(8)2
Avg EPS beat(8)-8.77%
EPS beat(12)3
Avg EPS beat(12)-7.3%
EPS beat(16)6
Avg EPS beat(16)-4.39%
Revenue beat(2)0
Avg Revenue beat(2)-7.5%
Min Revenue beat(2)-7.51%
Max Revenue beat(2)-7.49%
Revenue beat(4)1
Avg Revenue beat(4)-4.45%
Min Revenue beat(4)-7.51%
Max Revenue beat(4)2.47%
Revenue beat(8)2
Avg Revenue beat(8)-5.96%
Revenue beat(12)5
Avg Revenue beat(12)-0.69%
Revenue beat(16)8
Avg Revenue beat(16)1.3%
PT rev (1m)-50%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.91%
EPS NY rev (1m)41.78%
EPS NY rev (3m)41.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)97866.5%
Revenue NY rev (1m)-1.89%
Revenue NY rev (3m)-1.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.54
EYN/A
EPS(NY)-4.44
Fwd EYN/A
FCF(TTM)-5.95
FCFYN/A
OCF(TTM)-5.09
OCFYN/A
SpS11.01
BVpS-7.74
TBVpS-7.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -86.17%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 36.12%
FCFM N/A
ROA(3y)-59.67%
ROA(5y)-53.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.95%
GM growth 5Y-5.98%
F-Score4
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 109.05%
Cap/Sales 7.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.04
Quick Ratio 1.61
Altman-Z -9.96
F-Score4
WACC10.3%
ROIC/WACCN/A
Cap/Depr(3y)178%
Cap/Depr(5y)185.39%
Cap/Sales(3y)10.13%
Cap/Sales(5y)10.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.64%
EPS Next Y81.61%
EPS Next 2Y35.65%
EPS Next 3Y23.77%
EPS Next 5Y18.76%
Revenue 1Y (TTM)-3.95%
Revenue growth 3Y11.57%
Revenue growth 5Y13.41%
Sales Q2Q%11.96%
Revenue Next Year5.53%
Revenue Next 2Y10.65%
Revenue Next 3Y11.78%
Revenue Next 5Y18.62%
EBIT growth 1Y35.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.89%
EBIT Next 3Y24.47%
EBIT Next 5YN/A
FCF growth 1Y33.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.93%
OCF growth 3YN/A
OCF growth 5YN/A